Latest news articles

Added 1 hour ago Drug news

AcrySof IQ PanOptix intraocular lens (IOL) shows superior visual outcomes to the ZEISS AT LISA tri 839MP IOL in head to head study of cataract patients.- Alcon.

Alcon, unveils new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens (IOL)...

Added 1 hour ago Drug news

FDA approves Memo 4D mitral annuloplasty ring for treatment of mitral regurgitation.- LivaNova.

LivaNova PLC a market-leading medical technology company, announced it received FDA 510(k) clearance for its MEMO 4D semi-rigid mitral annuloplasty...

Added 1 hour ago Drug news

FDA Advisory Committee recommends premarket approval for Incraft AAA Stent Graft System for infrarenal abdominal aortic aneurysms. - Cordis/Cardinal Health.

Cardinal Health announced that the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee has provided a favorable...

Added 1 hour ago Drug news

CE Mark for CleanCision wound retraction and protection system.- Prescient Surgical,

Prescient Surgical announced it received CE Mark approval for its first-in-class, advanced technology CleanCision which fights and defends against the...

Added 1 hour ago Drug news

QuANTUM-R phase III study of AC 220 shows benefits for overall survival in acute myeloid leukemia.- Daiichi Sankyo.

Daiichi Sankyo announced updated positive results from the pivotal QuANTUM-R phase III study of AC 220 (quizartinib) which showed that...

Added 1 day ago Drug news

Complete Response Letter for Furoscix, a proposed treatment of edema or fluid overload in patients with heart failure.- sc Pharmaceuticals.

scPharmaceuticals Inc., announced the Company received a Complete Response Letter (CRL) from the FDA regarding the 505(b)(2) application for Furoscix,...

Added 1 day ago Drug news

Dexcom G6 continuous glucose monitor for diabetes receives CE Mark.- Dexcom.

Dexcom, Inc. a leader in continuous glucose monitoring (CGM), announced that the company has received CE Mark for its Dexcom...

Added 1 day ago Drug news

Teva discontinues the ENFORCE trial of fremanezumab for chronic cluster headache but the episodic cluster headache part of the study continues as planned.

Teva Pharmaceutical Industries Ltd. announced a change in the clinical development program of fremanezumab in chronic cluster headache . The...

Added 1 day ago Drug news

Fourteen months results from JULIET trial of Kymriah for patients with DLBCL.- Novartis

Novartis announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah (tisagenlecleucel) when...

Added 2 days ago Drug news

NICE does not recommend Perjeta + Herceptin combination to treat HER2-positive early breast cancer. Roche.

The National Institute for Health and Care Excellence (NICE) released draft guidance recommending against NHS use of combination Perjeta and...

Search all news articles